Overexpression of TOP2A and POLA2 has been strongly associated with enhanced cancer cell proliferation, and the observed downregulation of these proteins following ST1926 treatment indicates a potential reduction in cellular proliferation activity [42,43,44,45]. The gene discussed is POLA2; the disease is cancer.